September 10, 2020

We’ve got some friends in Congress coming to our aid to preserve compounded hormone therapy

Four representatives — Jaime Herrera Beutler, Henry Cuellar, Mark Pocan, and David P. Roe, M.D. — have written a letter to FDA Commissioner Stephen Hahn expressing their concern with the NASEM report. That’s the FDA-commissioned “study” that suggested limiting the availability of cBHT, despite the fact that it is used successfully by millions of people.

“[W]e ask the agency to consider the severely negative impact some of NASEM’s recommendations would have on patients,” they wrote, laying out some of the very issues APC has been pointing out since the NASEM report came out.

Their top point: “Doctors and patients should decide the best therapy.” It’s that simple (although we would add “pharmacists” to that list).

WE NEED YOU: Ask YOUR member of Congress to sign on to the letter. A phone call or message, “Please sign the Pocan letter to FDA about compounded hormone therapy” can make a difference.

Read the Pocan et al letter itself here.

Read APC’s brief on the issue here.